MILPITAS, Calif.–(BUSINESS WIRE)–Elixir Medical, a developer of disruptive technologies to treat cardiovascular and peripheral disease, today announced it has been granted Breakthrough Device Designation by the U.S. Food and Drug Administration (FDA) for its DynamX® BTK System, a novel, adaptive implant for use in the treatment of narrowed or blocked vessels below-the-knee (BTK) in patients with chronic limb-threatening ischemia (CLTI). The DynamX Bioadaptor platform is a medical technology d
Tag: Elixir Medical
TCT 2023: Six-Month Clinical Data from DESyne® BDS Plus Randomized Controlled Trial (RCT) Support Safety and Effectiveness of World’s First Site-Specific Antithrombotic Drug Therapy
SAN FRANCISCO–(BUSINESS WIRE)–Elixir Medical, a developer of novel cardiovascular technologies, today announced positive six-month clinical data from the DESyne BDS Plus Randomized Controlled Trial (RCT) evaluating DESyne BDS Plus, the world’s first triple drug-eluting coronary implant with site-specific delivery of antithrombotic drugs versus a second-generation, durable polymer drug-eluting stent (DES). The study met its primary endpoint of target lesion failure (TLF) with no TLF events rep
Elixir Medical To Present Randomized Clinical Dataset Featuring World’s First Triple Drug-Eluting Coronary Implant Eluting Two Anticoagulants and Sirolimus at TCT 2023
MILPITAS, Calif.–(BUSINESS WIRE)–Elixir Medical, a developer of innovative cardiovascular technologies, announced it will present primary endpoint and 6-month data from its DESyne BDS Plus Randomized Clinical Trial (RCT), a prospective, multicenter, single-blind study, as part of The Innovation Program at the Transcatheter Cardiovascular Therapeutics (TCT) conference in San Francisco. The data […]
Elixir Medical Completes Submission of DynamX Coronary Bioadaptor System to Japan’s PMDA Agency for Regulatory Approval
MILPITAS, Calif.–(BUSINESS WIRE)–Elixir Medical, a developer of disruptive cardiovascular technologies, announced submission to Japan’s Pharmaceutical and Medical Device Agency (PMDA) for the approval of the DynamX® Coronary Bioadaptor System for the treatment of coronary artery disease (CAD). DynamX coronary bioadaptor was developed to overcome the limitations of drug-eluting stents (DES) and […]
Elixir Medical Completes Enrollment of INFINITY-SWEDEHEART Clinical Trial
MILPITAS, Calif.–(BUSINESS WIRE)–Elixir Medical, a developer of breakthrough cardiovascular technologies, today announced enrollment completion in INFINITY-SWEDEHEART, a prospective, multicenter, single-blind, randomized clinical trial of the DynamX® Coronary Bioadaptor System, the first metallic coronary artery implant that adapts to vessel physiology versus the Resolute Onyx™ Drug-Eluting Stent (DES). DynamX Bioadaptor is the […]
Elixir Medical To Announce Late-Breaking Clinical Data at EuroPCR 2023 Session Featuring World’s First Transforming Coronary Artery Implant Designed to Restore Vessel Physiology and Function
– 12-month clinical and imaging data from first multicenter, international, randomized controlled trial of DynamX® Bioadaptor vs. Resolute OnyxTM to be presented Wednesday, May 17 – – Elixir Medical’s DynamX Bioadaptor goes beyond traditional caged tube drug-eluting stents (DES), or the promise of bioresorbable scaffolds (BRS), and is designed to restore flow, […]
Elixir Medical Expands Leadership Team With Addition of Alexey Nepogodiev as Executive Vice President, Global Marketing
MILPITAS, Calif.–(BUSINESS WIRE)–Elixir Medical, a developer of innovative, drug-eluting cardiovascular devices, today announced it has appointed Alexey (Alex) Nepogodiev as Executive Vice President, Global Marketing. Alex possesses more than 20 years of leadership experience in successfully developing new markets and therapies in interventional cardiology, structural heart, and endovascular businesses worldwide. […]
DynamX Bioadaptor Restores Rotational Motion and Vessel Stress Reduction in New Study
Paper Published in Cardiovascular Revascularization Medicine Shows Innovative Coronary Artery Implant is Capable of Moving with Vessel, Unlike Conventional Stents MILPITAS, Calif.–(BUSINESS WIRE)–Elixir Medical, a developer of innovative, drug-eluting cardiovascular devices, today announced print publication of a study in the latest issue of Cardiovascular Revascularization Medicine that showed that the DynamX™ […]
Elixir Medical Strengthens Its Commercial Capabilities With the Addition of Alaeddin Ahram as Executive Vice President, International
MILPITAS, Calif.–(BUSINESS WIRE)–Elixir Medical, a developer of innovative, drug-eluting cardiovascular devices, today announced it has appointed Alaeddin Ahram as Executive Vice President, International. Mr. Ahram possesses more than 25 years of leadership experience and successes in building new markets and accelerating commercialization for novel medical devices across Asia, Europe, and […]
Elixir Medical Completes Enrollment in BIOADAPTOR Randomized Controlled Trial of DynamX Coronary Bioadaptor System
MILPITAS, Calif.–(BUSINESS WIRE)–Elixir Medical, a developer of innovative, drug-eluting cardiovascular devices, today announced completion of enrollment in the BIOADAPTOR randomized controlled trial (RCT). The BIOADAPTOR RCT is evaluating the DynamX™ Coronary Bioadaptor System, the first drug-eluting coronary artery implant that adapts to vessel physiology, allowing for the restoration of normal vessel […]
Recent
Ancora Heart Inc. Reports Two-Year Results Demonstrating Sustained Benefits of AccuCinch® System in Heart Failure Patients
Cardiawave Strengthens Leadership with Appointment of Jonathan Freeman as Board Chairman
AngioInsight Appoints Medtech Veteran Shlomi Nachman to Board of Directors; Announces Series A Round to Accelerate AI-Driven Advancement in Cardiology
Popular
- No commented posts yet